ARID1A and neuroendocrine carcinoma: SMARCB1 class tumors were associated with significantly worse disease-specific survival compared to cases from the NEC-like IDH2 (p = 0.012), NEC-like SMARCA4/ARID1A (p < 0.001) or ACC class (p = 0.004).